nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—ESR1—liver cancer	0.401	1	CbGaD
Medroxyprogesterone Acetate—AKR1C3—Doxorubicin—liver cancer	0.262	0.766	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Sorafenib—liver cancer	0.0341	0.0998	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Sorafenib—liver cancer	0.0238	0.0696	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Sorafenib—liver cancer	0.0138	0.0405	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Doxorubicin—liver cancer	0.00839	0.0245	CbGbCtD
Medroxyprogesterone Acetate—Ethynodiol—ESR1—liver cancer	0.00064	0.416	CrCbGaD
Medroxyprogesterone Acetate—Fluoxymesterone—ESR1—liver cancer	0.000317	0.206	CrCbGaD
Medroxyprogesterone Acetate—Increased appetite—Doxorubicin—liver cancer	0.000188	0.00128	CcSEcCtD
Medroxyprogesterone Acetate—Migraine—Epirubicin—liver cancer	0.000188	0.00128	CcSEcCtD
Medroxyprogesterone Acetate—Affect lability—Epirubicin—liver cancer	0.000188	0.00128	CcSEcCtD
Medroxyprogesterone Acetate—Menopausal symptoms—Doxorubicin—liver cancer	0.000188	0.00127	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Sorafenib—liver cancer	0.000187	0.00127	CcSEcCtD
Medroxyprogesterone Acetate—Face oedema—Epirubicin—liver cancer	0.000185	0.00125	CcSEcCtD
Medroxyprogesterone Acetate—Purpura—Doxorubicin—liver cancer	0.000184	0.00124	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000183	0.00124	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Sorafenib—liver cancer	0.000183	0.00124	CcSEcCtD
Medroxyprogesterone Acetate—Hypoglycaemia—Doxorubicin—liver cancer	0.000181	0.00123	CcSEcCtD
Medroxyprogesterone Acetate—Mood swings—Epirubicin—liver cancer	0.000181	0.00123	CcSEcCtD
Medroxyprogesterone Acetate—Cerebrovascular accident—Doxorubicin—liver cancer	0.000181	0.00122	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Sorafenib—liver cancer	0.00018	0.00122	CcSEcCtD
Medroxyprogesterone Acetate—Ataxia—Epirubicin—liver cancer	0.00018	0.00122	CcSEcCtD
Medroxyprogesterone Acetate—Blood creatinine increased—Epirubicin—liver cancer	0.000179	0.00121	CcSEcCtD
Medroxyprogesterone Acetate—Pain in extremity—Doxorubicin—liver cancer	0.000177	0.0012	CcSEcCtD
Medroxyprogesterone Acetate—Osteoarthritis—Doxorubicin—liver cancer	0.000177	0.0012	CcSEcCtD
Medroxyprogesterone Acetate—Dry skin—Epirubicin—liver cancer	0.000175	0.00119	CcSEcCtD
Medroxyprogesterone Acetate—Orthostatic hypotension—Epirubicin—liver cancer	0.000175	0.00118	CcSEcCtD
Medroxyprogesterone Acetate—Migraine—Doxorubicin—liver cancer	0.000174	0.00118	CcSEcCtD
Medroxyprogesterone Acetate—Affect lability—Doxorubicin—liver cancer	0.000174	0.00118	CcSEcCtD
Medroxyprogesterone Acetate—Hypokalaemia—Epirubicin—liver cancer	0.000174	0.00118	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Sorafenib—liver cancer	0.000174	0.00118	CcSEcCtD
Medroxyprogesterone Acetate—Breast disorder—Epirubicin—liver cancer	0.000173	0.00117	CcSEcCtD
Medroxyprogesterone Acetate—Nasopharyngitis—Epirubicin—liver cancer	0.000171	0.00116	CcSEcCtD
Medroxyprogesterone Acetate—Face oedema—Doxorubicin—liver cancer	0.000171	0.00116	CcSEcCtD
Medroxyprogesterone Acetate—Muscular weakness—Epirubicin—liver cancer	0.000169	0.00114	CcSEcCtD
Medroxyprogesterone Acetate—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000169	0.00114	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Sorafenib—liver cancer	0.000168	0.00114	CcSEcCtD
Medroxyprogesterone Acetate—Mood swings—Doxorubicin—liver cancer	0.000168	0.00114	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal distension—Epirubicin—liver cancer	0.000166	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Ataxia—Doxorubicin—liver cancer	0.000166	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Blood creatinine increased—Doxorubicin—liver cancer	0.000166	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Influenza—Epirubicin—liver cancer	0.000165	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Epirubicin—liver cancer	0.000165	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Dysphagia—Epirubicin—liver cancer	0.000165	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Dry skin—Doxorubicin—liver cancer	0.000162	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Sorafenib—liver cancer	0.000162	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Orthostatic hypotension—Doxorubicin—liver cancer	0.000162	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Hypokalaemia—Doxorubicin—liver cancer	0.000161	0.00109	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Sorafenib—liver cancer	0.00016	0.00109	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Sorafenib—liver cancer	0.00016	0.00109	CcSEcCtD
Medroxyprogesterone Acetate—Breast disorder—Doxorubicin—liver cancer	0.00016	0.00108	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Sorafenib—liver cancer	0.000159	0.00108	CcSEcCtD
Medroxyprogesterone Acetate—Bronchitis—Epirubicin—liver cancer	0.000159	0.00108	CcSEcCtD
Medroxyprogesterone Acetate—Nasopharyngitis—Doxorubicin—liver cancer	0.000158	0.00107	CcSEcCtD
Medroxyprogesterone Acetate—Progesterone—ESR1—liver cancer	0.000157	0.102	CrCbGaD
Medroxyprogesterone Acetate—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000156	0.00106	CcSEcCtD
Medroxyprogesterone Acetate—Muscular weakness—Doxorubicin—liver cancer	0.000156	0.00106	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Epirubicin—liver cancer	0.000155	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal distension—Doxorubicin—liver cancer	0.000154	0.00104	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Epirubicin—liver cancer	0.000154	0.00104	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Doxorubicin—liver cancer	0.000153	0.00104	CcSEcCtD
Medroxyprogesterone Acetate—Influenza—Doxorubicin—liver cancer	0.000153	0.00104	CcSEcCtD
Medroxyprogesterone Acetate—Dysphagia—Doxorubicin—liver cancer	0.000153	0.00104	CcSEcCtD
Medroxyprogesterone Acetate—Pollakiuria—Epirubicin—liver cancer	0.000153	0.00104	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Sorafenib—liver cancer	0.000151	0.00102	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Epirubicin—liver cancer	0.00015	0.00102	CcSEcCtD
Medroxyprogesterone Acetate—Weight decreased—Epirubicin—liver cancer	0.00015	0.00101	CcSEcCtD
Medroxyprogesterone Acetate—Hyperglycaemia—Epirubicin—liver cancer	0.000149	0.00101	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Epirubicin—liver cancer	0.000147	0.000999	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Epirubicin—liver cancer	0.000147	0.000999	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Epirubicin—liver cancer	0.000147	0.000999	CcSEcCtD
Medroxyprogesterone Acetate—Bronchitis—Doxorubicin—liver cancer	0.000147	0.000997	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Epirubicin—liver cancer	0.000144	0.000979	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Epirubicin—liver cancer	0.000144	0.000974	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Epirubicin—liver cancer	0.000144	0.000974	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Epirubicin—liver cancer	0.000143	0.000971	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Doxorubicin—liver cancer	0.000143	0.00097	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000142	0.000964	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Epirubicin—liver cancer	0.000141	0.000958	CcSEcCtD
Medroxyprogesterone Acetate—Pollakiuria—Doxorubicin—liver cancer	0.000141	0.000958	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Epirubicin—liver cancer	0.000139	0.000945	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Doxorubicin—liver cancer	0.000139	0.000944	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Epirubicin—liver cancer	0.000139	0.000942	CcSEcCtD
Medroxyprogesterone Acetate—Weight decreased—Doxorubicin—liver cancer	0.000138	0.000938	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Epirubicin—liver cancer	0.000138	0.000937	CcSEcCtD
Medroxyprogesterone Acetate—Hyperglycaemia—Doxorubicin—liver cancer	0.000138	0.000935	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Doxorubicin—liver cancer	0.000136	0.000924	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Doxorubicin—liver cancer	0.000136	0.000924	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Doxorubicin—liver cancer	0.000136	0.000924	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Epirubicin—liver cancer	0.000135	0.000913	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Doxorubicin—liver cancer	0.000134	0.000906	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Epirubicin—liver cancer	0.000133	0.000901	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Doxorubicin—liver cancer	0.000133	0.000901	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Doxorubicin—liver cancer	0.000133	0.000901	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Doxorubicin—liver cancer	0.000133	0.000899	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Epirubicin—liver cancer	0.000132	0.000897	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Epirubicin—liver cancer	0.000132	0.000897	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Epirubicin—liver cancer	0.000131	0.00089	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Doxorubicin—liver cancer	0.000131	0.000886	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Epirubicin—liver cancer	0.000131	0.000886	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Epirubicin—liver cancer	0.00013	0.000884	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Epirubicin—liver cancer	0.00013	0.000881	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Epirubicin—liver cancer	0.00013	0.000879	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Doxorubicin—liver cancer	0.000129	0.000874	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Doxorubicin—liver cancer	0.000129	0.000872	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Doxorubicin—liver cancer	0.000128	0.000867	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Epirubicin—liver cancer	0.000128	0.000864	CcSEcCtD
Medroxyprogesterone Acetate—Progesterone—CYP1A1—liver cancer	0.000126	0.0817	CrCbGaD
Medroxyprogesterone Acetate—Erythema multiforme—Epirubicin—liver cancer	0.000125	0.000848	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Doxorubicin—liver cancer	0.000125	0.000845	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Epirubicin—liver cancer	0.000124	0.000838	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Epirubicin—liver cancer	0.000123	0.000836	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Doxorubicin—liver cancer	0.000123	0.000834	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Epirubicin—liver cancer	0.000123	0.000832	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Doxorubicin—liver cancer	0.000122	0.00083	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Doxorubicin—liver cancer	0.000122	0.00083	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Doxorubicin—liver cancer	0.000122	0.000824	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Doxorubicin—liver cancer	0.000121	0.00082	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Doxorubicin—liver cancer	0.000121	0.000818	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Doxorubicin—liver cancer	0.00012	0.000816	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Epirubicin—liver cancer	0.00012	0.000814	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Doxorubicin—liver cancer	0.00012	0.000814	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Epirubicin—liver cancer	0.00012	0.00081	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Epirubicin—liver cancer	0.000119	0.000808	CcSEcCtD
Medroxyprogesterone Acetate—Testosterone—CYP1A1—liver cancer	0.000119	0.0772	CrCbGaD
Medroxyprogesterone Acetate—Chills—Epirubicin—liver cancer	0.000119	0.000805	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Doxorubicin—liver cancer	0.000118	0.0008	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Epirubicin—liver cancer	0.000117	0.000793	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Epirubicin—liver cancer	0.000116	0.000786	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Doxorubicin—liver cancer	0.000116	0.000785	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Epirubicin—liver cancer	0.000115	0.000781	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Epirubicin—liver cancer	0.000115	0.000781	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Doxorubicin—liver cancer	0.000114	0.000776	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Doxorubicin—liver cancer	0.000114	0.000774	CcSEcCtD
Medroxyprogesterone Acetate—Methyltestosterone—ALB—liver cancer	0.000114	0.0741	CrCbGaD
Medroxyprogesterone Acetate—Cardiac disorder—Doxorubicin—liver cancer	0.000114	0.00077	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Epirubicin—liver cancer	0.000114	0.000769	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Epirubicin—liver cancer	0.000113	0.000766	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Epirubicin—liver cancer	0.000113	0.000765	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Epirubicin—liver cancer	0.000112	0.000758	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Epirubicin—liver cancer	0.000111	0.000755	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Doxorubicin—liver cancer	0.000111	0.000753	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Epirubicin—liver cancer	0.000111	0.000751	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Doxorubicin—liver cancer	0.000111	0.00075	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Doxorubicin—liver cancer	0.00011	0.000748	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Doxorubicin—liver cancer	0.00011	0.000745	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Doxorubicin—liver cancer	0.000108	0.000733	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Doxorubicin—liver cancer	0.000107	0.000727	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Epirubicin—liver cancer	0.000107	0.000724	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Doxorubicin—liver cancer	0.000107	0.000722	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Doxorubicin—liver cancer	0.000107	0.000722	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Epirubicin—liver cancer	0.000106	0.000722	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Epirubicin—liver cancer	0.000106	0.000718	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Doxorubicin—liver cancer	0.000105	0.000712	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Doxorubicin—liver cancer	0.000105	0.000709	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Doxorubicin—liver cancer	0.000104	0.000707	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Epirubicin—liver cancer	0.000104	0.000704	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Doxorubicin—liver cancer	0.000104	0.000702	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Epirubicin—liver cancer	0.000103	0.000701	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Epirubicin—liver cancer	0.000103	0.0007	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Doxorubicin—liver cancer	0.000103	0.000699	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Doxorubicin—liver cancer	0.000102	0.000695	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Epirubicin—liver cancer	0.000102	0.00069	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Epirubicin—liver cancer	0.000101	0.000686	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Epirubicin—liver cancer	9.98e-05	0.000676	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Doxorubicin—liver cancer	9.89e-05	0.00067	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Doxorubicin—liver cancer	9.85e-05	0.000668	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Epirubicin—liver cancer	9.81e-05	0.000665	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Epirubicin—liver cancer	9.81e-05	0.000665	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Epirubicin—liver cancer	9.81e-05	0.000665	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Doxorubicin—liver cancer	9.79e-05	0.000664	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Epirubicin—liver cancer	9.77e-05	0.000662	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	9.74e-05	0.00066	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Epirubicin—liver cancer	9.69e-05	0.000657	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Doxorubicin—liver cancer	9.61e-05	0.000651	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Epirubicin—liver cancer	9.59e-05	0.00065	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Doxorubicin—liver cancer	9.58e-05	0.000649	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Doxorubicin—liver cancer	9.56e-05	0.000648	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Epirubicin—liver cancer	9.48e-05	0.000643	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Doxorubicin—liver cancer	9.42e-05	0.000638	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Epirubicin—liver cancer	9.4e-05	0.000637	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Epirubicin—liver cancer	9.4e-05	0.000637	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Doxorubicin—liver cancer	9.37e-05	0.000635	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Epirubicin—liver cancer	9.34e-05	0.000633	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Epirubicin—liver cancer	9.25e-05	0.000627	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Doxorubicin—liver cancer	9.23e-05	0.000626	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Epirubicin—liver cancer	9.22e-05	0.000625	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Epirubicin—liver cancer	9.2e-05	0.000624	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Epirubicin—liver cancer	9.17e-05	0.000622	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Epirubicin—liver cancer	9.13e-05	0.000619	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Epirubicin—liver cancer	9.09e-05	0.000616	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Doxorubicin—liver cancer	9.07e-05	0.000615	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Doxorubicin—liver cancer	9.07e-05	0.000615	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Doxorubicin—liver cancer	9.07e-05	0.000615	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Doxorubicin—liver cancer	9.04e-05	0.000613	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	9.01e-05	0.000611	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Doxorubicin—liver cancer	8.96e-05	0.000608	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Epirubicin—liver cancer	8.96e-05	0.000607	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Doxorubicin—liver cancer	8.87e-05	0.000602	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Epirubicin—liver cancer	8.78e-05	0.000595	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Doxorubicin—liver cancer	8.77e-05	0.000595	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Doxorubicin—liver cancer	8.7e-05	0.00059	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Doxorubicin—liver cancer	8.7e-05	0.00059	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Doxorubicin—liver cancer	8.64e-05	0.000586	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Epirubicin—liver cancer	8.56e-05	0.000581	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Doxorubicin—liver cancer	8.56e-05	0.00058	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Doxorubicin—liver cancer	8.53e-05	0.000578	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Doxorubicin—liver cancer	8.52e-05	0.000577	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Epirubicin—liver cancer	8.5e-05	0.000576	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Doxorubicin—liver cancer	8.49e-05	0.000575	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Doxorubicin—liver cancer	8.45e-05	0.000573	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Epirubicin—liver cancer	8.44e-05	0.000572	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Doxorubicin—liver cancer	8.41e-05	0.00057	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Epirubicin—liver cancer	8.38e-05	0.000568	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Epirubicin—liver cancer	8.36e-05	0.000566	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Doxorubicin—liver cancer	8.29e-05	0.000562	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Epirubicin—liver cancer	8.27e-05	0.000561	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Epirubicin—liver cancer	8.17e-05	0.000554	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Doxorubicin—liver cancer	8.13e-05	0.000551	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Epirubicin—liver cancer	8.12e-05	0.00055	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Epirubicin—liver cancer	8.1e-05	0.000549	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Epirubicin—liver cancer	8.04e-05	0.000545	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Doxorubicin—liver cancer	7.92e-05	0.000537	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Doxorubicin—liver cancer	7.87e-05	0.000533	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Doxorubicin—liver cancer	7.81e-05	0.000529	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Doxorubicin—liver cancer	7.75e-05	0.000526	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Epirubicin—liver cancer	7.75e-05	0.000525	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Doxorubicin—liver cancer	7.73e-05	0.000524	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Epirubicin—liver cancer	7.69e-05	0.000521	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Doxorubicin—liver cancer	7.66e-05	0.000519	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Doxorubicin—liver cancer	7.56e-05	0.000513	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Doxorubicin—liver cancer	7.51e-05	0.000509	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Doxorubicin—liver cancer	7.5e-05	0.000508	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Epirubicin—liver cancer	7.47e-05	0.000506	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Doxorubicin—liver cancer	7.44e-05	0.000504	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Epirubicin—liver cancer	7.43e-05	0.000504	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Epirubicin—liver cancer	7.43e-05	0.000504	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Doxorubicin—liver cancer	7.17e-05	0.000486	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Doxorubicin—liver cancer	7.11e-05	0.000482	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Epirubicin—liver cancer	6.93e-05	0.000469	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Doxorubicin—liver cancer	6.91e-05	0.000468	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Doxorubicin—liver cancer	6.88e-05	0.000466	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Doxorubicin—liver cancer	6.88e-05	0.000466	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Epirubicin—liver cancer	6.74e-05	0.000457	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Epirubicin—liver cancer	6.65e-05	0.000451	CcSEcCtD
Medroxyprogesterone Acetate—Testosterone—ALB—liver cancer	6.62e-05	0.043	CrCbGaD
Medroxyprogesterone Acetate—Diarrhoea—Epirubicin—liver cancer	6.43e-05	0.000436	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Doxorubicin—liver cancer	6.41e-05	0.000434	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Doxorubicin—liver cancer	6.24e-05	0.000423	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Epirubicin—liver cancer	6.22e-05	0.000421	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Doxorubicin—liver cancer	6.15e-05	0.000417	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Epirubicin—liver cancer	5.98e-05	0.000405	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Doxorubicin—liver cancer	5.95e-05	0.000403	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Epirubicin—liver cancer	5.93e-05	0.000402	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Epirubicin—liver cancer	5.92e-05	0.000401	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Epirubicin—liver cancer	5.89e-05	0.000399	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Doxorubicin—liver cancer	5.75e-05	0.00039	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Epirubicin—liver cancer	5.58e-05	0.000379	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Doxorubicin—liver cancer	5.53e-05	0.000375	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Doxorubicin—liver cancer	5.48e-05	0.000372	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Doxorubicin—liver cancer	5.48e-05	0.000371	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Doxorubicin—liver cancer	5.45e-05	0.000369	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Doxorubicin—liver cancer	5.17e-05	0.00035	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CSF2—liver cancer	1.67e-05	0.000155	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—F2—liver cancer	1.66e-05	0.000154	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—ALB—liver cancer	1.65e-05	0.000153	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—H2AFX—liver cancer	1.65e-05	0.000153	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CDKN1B—liver cancer	1.63e-05	0.000152	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—UGDH—liver cancer	1.6e-05	0.000149	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	1.6e-05	0.000148	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CG—liver cancer	1.59e-05	0.000148	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—APC—liver cancer	1.59e-05	0.000148	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MAPK14—liver cancer	1.59e-05	0.000147	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTA4—liver cancer	1.57e-05	0.000146	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—ESR1—liver cancer	1.56e-05	0.000144	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CTNNB1—liver cancer	1.54e-05	0.000143	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.53e-05	0.000142	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTA2—liver cancer	1.53e-05	0.000142	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ADAM17—liver cancer	1.52e-05	0.000141	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CDKN1A—liver cancer	1.51e-05	0.00014	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—EPT1—liver cancer	1.51e-05	0.00014	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—BRAF—liver cancer	1.5e-05	0.000139	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TERT—liver cancer	1.49e-05	0.000138	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—H2AFX—liver cancer	1.49e-05	0.000138	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTA1—liver cancer	1.48e-05	0.000137	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CPT1B—liver cancer	1.47e-05	0.000137	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GLUL—liver cancer	1.47e-05	0.000137	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—AKT1—liver cancer	1.47e-05	0.000136	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—H2AFX—liver cancer	1.46e-05	0.000136	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NAT2—liver cancer	1.46e-05	0.000135	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PIK3CB—liver cancer	1.46e-05	0.000135	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PSMA4—liver cancer	1.43e-05	0.000133	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PSMD10—liver cancer	1.43e-05	0.000133	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TAT—liver cancer	1.43e-05	0.000133	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NR1H4—liver cancer	1.42e-05	0.000132	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—PPARG—liver cancer	1.42e-05	0.000132	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.4e-05	0.00013	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CD—liver cancer	1.4e-05	0.00013	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ALDOB—liver cancer	1.4e-05	0.00013	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTA3—liver cancer	1.4e-05	0.000129	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SERPINE1—liver cancer	1.38e-05	0.000128	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KDR—liver cancer	1.36e-05	0.000126	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MAPK14—liver cancer	1.35e-05	0.000126	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—STAT3—liver cancer	1.35e-05	0.000125	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CRABP1—liver cancer	1.33e-05	0.000124	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ESR1—liver cancer	1.33e-05	0.000123	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PPARA—liver cancer	1.32e-05	0.000123	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—F2—liver cancer	1.31e-05	0.000122	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PPARA—liver cancer	1.3e-05	0.000121	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—MYC—liver cancer	1.29e-05	0.00012	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—SERPINE1—liver cancer	1.28e-05	0.000119	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTA4—liver cancer	1.28e-05	0.000118	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—MYC—liver cancer	1.28e-05	0.000118	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—APC—liver cancer	1.26e-05	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CG—liver cancer	1.26e-05	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MYC—liver cancer	1.25e-05	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—RAF1—liver cancer	1.25e-05	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.25e-05	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—TGFB1—liver cancer	1.25e-05	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTA2—liver cancer	1.24e-05	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MAPK14—liver cancer	1.22e-05	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MTOR—liver cancer	1.22e-05	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CB—liver cancer	1.22e-05	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MAPK14—liver cancer	1.2e-05	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.2e-05	0.000111	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTA1—liver cancer	1.2e-05	0.000111	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NAT2—liver cancer	1.19e-05	0.00011	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—ESR1—liver cancer	1.18e-05	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—BRAF—liver cancer	1.18e-05	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HPGDS—liver cancer	1.17e-05	0.000108	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.16e-05	0.000108	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—KRAS—liver cancer	1.16e-05	0.000107	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CDKN1B—liver cancer	1.14e-05	0.000106	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.14e-05	0.000106	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ALDOB—liver cancer	1.14e-05	0.000106	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CASP3—liver cancer	1.12e-05	0.000104	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL2—liver cancer	1.12e-05	0.000104	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PRKCE—liver cancer	1.11e-05	0.000103	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CD—liver cancer	1.1e-05	0.000102	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PPARG—liver cancer	1.09e-05	0.000101	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CCND1—liver cancer	1.09e-05	0.000101	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SERPINE1—liver cancer	1.09e-05	0.000101	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—JUN—liver cancer	1.09e-05	0.000101	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CRABP1—liver cancer	1.09e-05	0.000101	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CTNNB1—liver cancer	1.08e-05	0.0001	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PPARG—liver cancer	1.08e-05	9.99e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—MYC—liver cancer	1.06e-05	9.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PIK3CA—liver cancer	1.06e-05	9.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MMP9—liver cancer	1.06e-05	9.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.06e-05	9.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CDKN1A—liver cancer	1.06e-05	9.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IGF2—liver cancer	1.05e-05	9.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.04e-05	9.67e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PSMA4—liver cancer	1.04e-05	9.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PSMD10—liver cancer	1.04e-05	9.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MAPK8—liver cancer	1.03e-05	9.56e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GOT2—liver cancer	1.01e-05	9.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—SERPINE1—liver cancer	9.85e-06	9.13e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—RAF1—liver cancer	9.85e-06	9.13e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—HRAS—liver cancer	9.82e-06	9.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CSF2—liver cancer	9.81e-06	9.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	9.78e-06	9.07e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CPT1B—liver cancer	9.71e-06	9.01e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GLUL—liver cancer	9.71e-06	9.01e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—SERPINE1—liver cancer	9.7e-06	9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—H2AFX—liver cancer	9.67e-06	8.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MTOR—liver cancer	9.62e-06	8.92e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CB—liver cancer	9.62e-06	8.92e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VEGFA—liver cancer	9.52e-06	8.82e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP2E1—liver cancer	9.51e-06	8.82e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HPGDS—liver cancer	9.49e-06	8.8e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	9.44e-06	8.75e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—STAT3—liver cancer	9.42e-06	8.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—IL6—liver cancer	9.4e-06	8.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NR1H4—liver cancer	9.37e-06	8.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTA3—liver cancer	9.21e-06	8.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	9.21e-06	8.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN1B—liver cancer	9.03e-06	8.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYCS—liver cancer	8.9e-06	8.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PIK3CA—liver cancer	8.89e-06	8.24e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CASP3—liver cancer	8.85e-06	8.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL2—liver cancer	8.83e-06	8.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MYC—liver cancer	8.76e-06	8.12e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TERT—liver cancer	8.74e-06	8.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TGFB1—liver cancer	8.73e-06	8.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GGT1—liver cancer	8.73e-06	8.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GOT1—liver cancer	8.73e-06	8.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—AKT1—liver cancer	8.67e-06	8.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CCND1—liver cancer	8.61e-06	7.98e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	8.6e-06	7.97e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—JUN—liver cancer	8.59e-06	7.97e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CTNNB1—liver cancer	8.53e-06	7.91e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	8.49e-06	7.87e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PSMA4—liver cancer	8.46e-06	7.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PSMD10—liver cancer	8.46e-06	7.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTA4—liver cancer	8.42e-06	7.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MMP9—liver cancer	8.36e-06	7.75e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN1A—liver cancer	8.33e-06	7.72e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GOT2—liver cancer	8.23e-06	7.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTA2—liver cancer	8.21e-06	7.61e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MAPK8—liver cancer	8.13e-06	7.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MYC—liver cancer	8.09e-06	7.5e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KRAS—liver cancer	8.09e-06	7.5e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KDR—liver cancer	8e-06	7.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MAPK14—liver cancer	7.94e-06	7.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTA1—liver cancer	7.92e-06	7.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTP1—liver cancer	7.84e-06	7.27e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NAT2—liver cancer	7.83e-06	7.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP2E1—liver cancer	7.74e-06	7.18e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HMOX1—liver cancer	7.73e-06	7.17e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—F2—liver cancer	7.7e-06	7.14e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ALDOB—liver cancer	7.51e-06	6.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VEGFA—liver cancer	7.51e-06	6.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.49e-06	6.95e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—STAT3—liver cancer	7.43e-06	6.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CA—liver cancer	7.43e-06	6.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—APC—liver cancer	7.37e-06	6.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CG—liver cancer	7.37e-06	6.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—AKT1—liver cancer	7.37e-06	6.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—AKT1—liver cancer	7.26e-06	6.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYCS—liver cancer	7.24e-06	6.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTM1—liver cancer	7.21e-06	6.68e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—liver cancer	7.19e-06	6.67e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CRABP1—liver cancer	7.16e-06	6.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GOT1—liver cancer	7.1e-06	6.59e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GGT1—liver cancer	7.1e-06	6.59e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—BRAF—liver cancer	6.92e-06	6.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MYC—liver cancer	6.91e-06	6.4e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TGFB1—liver cancer	6.89e-06	6.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HRAS—liver cancer	6.88e-06	6.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP1A1—liver cancer	6.83e-06	6.33e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL6—liver cancer	6.58e-06	6.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CD—liver cancer	6.48e-06	6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SERPINE1—liver cancer	6.41e-06	5.94e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KRAS—liver cancer	6.38e-06	5.92e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTP1—liver cancer	6.38e-06	5.92e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—MTHFR—liver cancer	6.37e-06	5.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HMOX1—liver cancer	6.29e-06	5.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HPGDS—liver cancer	6.26e-06	5.8e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PPARA—liver cancer	6.25e-06	5.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MYC—liver cancer	6.23e-06	5.78e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MYC—liver cancer	6.14e-06	5.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—AKT1—liver cancer	6.07e-06	5.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTM1—liver cancer	5.86e-06	5.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CA—liver cancer	5.86e-06	5.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RAF1—liver cancer	5.78e-06	5.36e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—liver cancer	5.67e-06	5.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CB—liver cancer	5.64e-06	5.23e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MTOR—liver cancer	5.64e-06	5.23e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—AKT1—liver cancer	5.61e-06	5.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.61e-06	5.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PSMA4—liver cancer	5.58e-06	5.17e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PSMD10—liver cancer	5.58e-06	5.17e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP1A1—liver cancer	5.56e-06	5.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GOT2—liver cancer	5.43e-06	5.03e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HRAS—liver cancer	5.42e-06	5.03e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CG—liver cancer	5.35e-06	4.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN1B—liver cancer	5.3e-06	4.91e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CASP3—liver cancer	5.19e-06	4.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL6—liver cancer	5.19e-06	4.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL2—liver cancer	5.18e-06	4.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—MTHFR—liver cancer	5.18e-06	4.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PPARG—liver cancer	5.16e-06	4.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP2E1—liver cancer	5.1e-06	4.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PPARA—liver cancer	5.08e-06	4.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CCND1—liver cancer	5.05e-06	4.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—JUN—liver cancer	5.04e-06	4.68e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CTNNB1—liver cancer	5e-06	4.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MMP9—liver cancer	4.91e-06	4.55e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN1A—liver cancer	4.89e-06	4.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—AKT1—liver cancer	4.79e-06	4.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYCS—liver cancer	4.77e-06	4.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MAPK8—liver cancer	4.77e-06	4.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CD—liver cancer	4.7e-06	4.36e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GGT1—liver cancer	4.69e-06	4.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GOT1—liver cancer	4.69e-06	4.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ALB—liver cancer	4.64e-06	4.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.57e-06	4.24e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VEGFA—liver cancer	4.41e-06	4.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—STAT3—liver cancer	4.36e-06	4.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CG—liver cancer	4.35e-06	4.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—AKT1—liver cancer	4.32e-06	4.01e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—AKT1—liver cancer	4.26e-06	3.95e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTP1—liver cancer	4.21e-06	3.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PPARG—liver cancer	4.2e-06	3.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HMOX1—liver cancer	4.15e-06	3.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CB—liver cancer	4.1e-06	3.8e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MYC—liver cancer	4.05e-06	3.76e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TGFB1—liver cancer	4.04e-06	3.75e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTM1—liver cancer	3.87e-06	3.59e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CD—liver cancer	3.83e-06	3.55e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ALB—liver cancer	3.78e-06	3.5e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KRAS—liver cancer	3.75e-06	3.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP1A1—liver cancer	3.67e-06	3.4e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CA—liver cancer	3.44e-06	3.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—MTHFR—liver cancer	3.42e-06	3.17e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PPARA—liver cancer	3.35e-06	3.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CB—liver cancer	3.34e-06	3.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—liver cancer	3.33e-06	3.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HRAS—liver cancer	3.18e-06	2.95e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL6—liver cancer	3.05e-06	2.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CG—liver cancer	2.87e-06	2.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKT1—liver cancer	2.81e-06	2.61e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PPARG—liver cancer	2.77e-06	2.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CD—liver cancer	2.52e-06	2.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CA—liver cancer	2.5e-06	2.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ALB—liver cancer	2.49e-06	2.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CB—liver cancer	2.2e-06	2.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—AKT1—liver cancer	2.04e-06	1.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CA—liver cancer	2.03e-06	1.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKT1—liver cancer	1.66e-06	1.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CA—liver cancer	1.34e-06	1.24e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKT1—liver cancer	1.1e-06	1.02e-05	CbGpPWpGaD
